Clinical Trial Update: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating adding atezolizumab to standard chemoradiation for limited-stage small cell lung cancer; the study is active but not curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-12